EMERALD: Updated Phase 3 Results by Duration of Prior CDK4/6i Treatment
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy…
Tagraxofusp: Phase 1 Study (+/- chemotherapy) in Pediatric Patients with R/R CD123 expressing Heme Malignancies
Phase I Study of Tagraxofusp +/- Chemotherapy in Pediatric Patients with R/R…
Tagraxofusp: Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial
Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis…
Tagraxofusp: Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP
Preliminary Results from an Observational Study of Patients with BPDCN Treated…
ELEVATE: A Phase 1b/2 Umbrella Study Evaluating Elacestrant in Various Combinations
ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating elacestrant in…
EMERALD: Phase 3 Subgroup Analysis
Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial…
EMERALD: Subgroup Analysis of patients with no prior chemotherapy
EMERALD: Subgroup analysis of patients with no prior chemotherapy in a phase 3…
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with…
Tagraxofusp in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial
TAG in Patients with CMML: Updated Results from Phase 1/2 Trial. ASH 2021. Oral…
Tagraxofusp: Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease
Tagraxofusp Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease.…